{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-063737","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.734619+00:00","generated_at":"2026-06-18T08:30:39.567532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled","bullets":["Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.","Cash, equivalents & short-term investments $424.6M as of Dec 31, 2022; runway into H2 2025.","First patient enrolled in THRIVE Phase 3 trial of VRDN-001 for active TED; topline mid-2024.","Initial proof-of-concept data for VRDN-001 in chronic TED expected Q2 2023.","Appointed Scott Myers as President and CEO in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-063737","json":"https://secwatch.observer/filing/0001193125-23-063737.json","markdown":"https://secwatch.observer/filing/0001193125-23-063737.md","text":"https://secwatch.observer/filing/0001193125-23-063737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/d478193d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:30:39.567532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac44d44cf8432809e0b92b56fc5105c710b93a9a","claim":"Viridian Therapeutics, Inc.\\DE reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 8, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}